Evolus Inc (NAS:EOLS)
$ 16.46 1.19 (7.79%) Market Cap: 1.04 Bil Enterprise Value: 996.53 Mil PE Ratio: 0 PB Ratio: 49.90 GF Score: 56/100

Evolus Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 10:40PM GMT
Release Date Price: $22.88 (+3.11%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

(technical difficulty)

everybody. My name is Jason Gerberry, the U.S. pharma analyst here at Bank of America. I am pleased to be introducing our next company presenter. I'm joined by David Moatazedi, CEO of Evolus. David's got a few slides. So Evolus, for many of you who don't know, we'll call them a commercial stage company tomorrow, but right now, they're a late-stage player in the aesthetic dermatology space. And so David has a slide he wants to show and then we'll jump into Q&A.

David Moatazedi
Evolus, Inc. - President, CEO & Director

Great. Thank you, Jason. And what's funny is I was about 2 weeks into my role here as President and CEO when I attended this BAML conference last year and had an opportunity to sit here across from you. So the company looks very different today than it did a year ago, roughly when I joined.

May I just take a few minutes for those of you that aren't familiar with Evolus to tell you a little bit about me and tell

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot